FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209888410> ?p ?o ?g. }

• W3209888410 endingPage "113901" @default.
• W3209888410 startingPage "113901" @default.
• W3209888410 abstract "Stroke therapy still lacks successful measures to improve post stroke recovery. Neurotrophin-3 (NT-3) is one promising candidate which has proven therapeutic benefit in motor recovery in acute experimental stroke. Post stroke, the immune system has opposing pathophysiological roles: pro-inflammatory cascades and immune cell infiltration into the brain exacerbate cell death while the peripheral immune response has only limited capabilities to fight infections during the acute and subacute phase. With time, anti-inflammatory mechanisms are supposed to support recovery of the ischemic damage within the brain parenchyma. However, interestingly, NT-3 can improve recovery in chronic neurological injury when combined with the pro-inflammatory stimulus lipopolysaccharide (LPS).We elucidated the impact of NT-3 on human monocyte and T cell activation as well as cytokine production ex vivo after stroke. In addition, we investigated the age-dependent availability of the high affinity NT-3 receptor TrkC upon LPS stimulation.Peripheral blood mononuclear cells (PBMCs) were isolated from acute stroke patients and controls and incubated with different dosages of NT-3 (10 and 100 ng/mL) and with or without LPS or anti-CD3/CD28 for 48 h. Total TrkC expression and cell activation (CD25, CD69 and HLA-DR) were assessed by FACS staining. IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21 and IL-22 were quantified by cytometric bead array.Most monocytes and only a small proportion of T cells expressed TrkC in blood from humans without stroke. Activation of cells from young humans (without strokes) using anti-CD3/CD28 or LPS partially reduced the proportion of monocytes expressing TrkC whilst they increased the proportion of T cells expressing TrkC. In contrast, activation of cells from elderly humans (without strokes) did not affect the proportion of monocytes expressing TrkC and only anti-CD3/CD28 led to an increase in the proportion of CD4+ T cells expressing TrkC. In blood from stroke patients or controls, NT-3 treatment reduced the percentage of monocytes and CD4+ and CD8+ T cells that were activated and reduced all cytokines investigated besides IL-21.NT-3 attenuated immune responses in cells from stroke patients and controls. The mechanism whereby human immune cells respond to NT-3 may be via TrkC receptors whose levels are regulated by stimulation. Further work is required to determine whether the induction of sensorimotor recovery in rodents by NT-3 after CNS injury is caused by this attenuation of the immune response." @default.
• W3209888410 created "2021-11-08" @default.
• W3209888410 creator A5008942740 @default.
• W3209888410 creator A5011547154 @default.
• W3209888410 creator A5042333379 @default.
• W3209888410 creator A5044066289 @default.
• W3209888410 creator A5047903147 @default.
• W3209888410 creator A5065202508 @default.
• W3209888410 creator A5087596924 @default.
• W3209888410 date "2022-01-01" @default.
• W3209888410 modified "2023-09-30" @default.
• W3209888410 title "Neurotrophin-3 attenuates human peripheral blood T cell and monocyte activation status and cytokine production post stroke" @default.
• W3209888410 cites W1514868251 @default.
• W3209888410 cites W1603728406 @default.
• W3209888410 cites W164913478 @default.
• W3209888410 cites W1817759654 @default.
• W3209888410 cites W1863551998 @default.
• W3209888410 cites W1967054754 @default.
• W3209888410 cites W1967635573 @default.
• W3209888410 cites W1987295549 @default.
• W3209888410 cites W1988768639 @default.
• W3209888410 cites W1997843836 @default.
• W3209888410 cites W2008886334 @default.
• W3209888410 cites W2031155651 @default.
• W3209888410 cites W2040916002 @default.
• W3209888410 cites W2045220317 @default.
• W3209888410 cites W2053218399 @default.
• W3209888410 cites W2056250989 @default.
• W3209888410 cites W2057133274 @default.
• W3209888410 cites W2078636545 @default.
• W3209888410 cites W2079133592 @default.
• W3209888410 cites W2084430660 @default.
• W3209888410 cites W2091399990 @default.
• W3209888410 cites W2091746603 @default.
• W3209888410 cites W2092706716 @default.
• W3209888410 cites W2093743668 @default.
• W3209888410 cites W2094425536 @default.
• W3209888410 cites W2097128866 @default.
• W3209888410 cites W2120819751 @default.
• W3209888410 cites W2131545168 @default.
• W3209888410 cites W2133956375 @default.
• W3209888410 cites W2143366980 @default.
• W3209888410 cites W2144662584 @default.
• W3209888410 cites W2150424204 @default.
• W3209888410 cites W2160008914 @default.
• W3209888410 cites W2168259263 @default.
• W3209888410 cites W2178937067 @default.
• W3209888410 cites W2610932550 @default.
• W3209888410 cites W2612659032 @default.
• W3209888410 cites W2767776410 @default.
• W3209888410 cites W2805242384 @default.
• W3209888410 cites W2883620619 @default.
• W3209888410 cites W2912654919 @default.
• W3209888410 cites W2914392737 @default.
• W3209888410 cites W2916055237 @default.
• W3209888410 cites W2947787568 @default.
• W3209888410 cites W3080273663 @default.
• W3209888410 cites W3164095329 @default.
• W3209888410 doi "https://doi.org/10.1016/j.expneurol.2021.113901" @default.
• W3209888410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34688600" @default.
• W3209888410 hasPublicationYear "2022" @default.
• W3209888410 type Work @default.
• W3209888410 sameAs 3209888410 @default.
• W3209888410 citedByCount "5" @default.
• W3209888410 countsByYear W32098884102022 @default.
• W3209888410 countsByYear W32098884102023 @default.
• W3209888410 crossrefType "journal-article" @default.
• W3209888410 hasAuthorship W3209888410A5008942740 @default.
• W3209888410 hasAuthorship W3209888410A5011547154 @default.
• W3209888410 hasAuthorship W3209888410A5042333379 @default.
• W3209888410 hasAuthorship W3209888410A5044066289 @default.
• W3209888410 hasAuthorship W3209888410A5047903147 @default.
• W3209888410 hasAuthorship W3209888410A5065202508 @default.
• W3209888410 hasAuthorship W3209888410A5087596924 @default.
• W3209888410 hasBestOaLocation W32098884101 @default.
• W3209888410 hasConcept C137061746 @default.
• W3209888410 hasConcept C17991360 @default.
• W3209888410 hasConcept C202751555 @default.
• W3209888410 hasConcept C203014093 @default.
• W3209888410 hasConcept C2776090121 @default.
• W3209888410 hasConcept C2776914184 @default.
• W3209888410 hasConcept C2778690821 @default.
• W3209888410 hasConcept C55493867 @default.
• W3209888410 hasConcept C71924100 @default.
• W3209888410 hasConcept C86803240 @default.
• W3209888410 hasConcept C8891405 @default.
• W3209888410 hasConceptScore W3209888410C137061746 @default.
• W3209888410 hasConceptScore W3209888410C17991360 @default.
• W3209888410 hasConceptScore W3209888410C202751555 @default.
• W3209888410 hasConceptScore W3209888410C203014093 @default.
• W3209888410 hasConceptScore W3209888410C2776090121 @default.
• W3209888410 hasConceptScore W3209888410C2776914184 @default.
• W3209888410 hasConceptScore W3209888410C2778690821 @default.
• W3209888410 hasConceptScore W3209888410C55493867 @default.
• W3209888410 hasConceptScore W3209888410C71924100 @default.
• W3209888410 hasConceptScore W3209888410C86803240 @default.
• W3209888410 hasConceptScore W3209888410C8891405 @default.
• W3209888410 hasFunder F4320314536 @default.

• next